CY 6022 is an Open Label Study to Collect Long-term Safety and Tolerability Data for Aficamten (CK-3773274)

Open to people ages 18-85

• Completion of a Cytokinetics trial investigating CK-3773274
• LVEF ≥55% at the Screening Visit

• Has taken any investigational study drug other than CK-3773274 within 30 days prior to screening
• Since completion of a previous trial of CK-3773274 has:
  • Developed new-onset paroxysmal or permanent atrial fibrillation requiring rhythm restoring treatment (eg, direct-current cardioversion, ablation procedure, or antiarrhythmic therapy) <30 days prior to screening. Patient may re-screen for CY 6022 after 30 days if heart rate (HR) <100 bpm and/or rhythm is stable >30 days
  • Undergone septal reduction therapy (surgical myectomy or transcatheter alcohol ablation) since the completion of a prior trial of CK-3773274.
• Has current obstructive coronary artery disease (>70% stenosis documented in one or more arteries)
• Has moderate or severe aortic valve stenosis
• Had a confirmed LVEF <40% with an associated dose interruption during CY 6021
• History of syncope or sustained ventricular tachyarrhythmia with exercise within 30 days prior to screening
• History of appropriate ICD shock within 30 days prior to screening
• Has received treatment with mavacamten